Fried, Frank, Harris, Shriver & Jacobson LLP acted as counsel to Catalent in its US$1.2 billion definitive agreement to acquire Paragon Bioservices. Catalent is a diversified global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Paragon Bioservices is a private-equity-backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. The transaction is expected to close in the second quarter of 2019.
The Fried Frank team was led by corporate partners Steven Epstein and Matthew V. Soran and included corporate partners Daniel J. Bursky and Joshua Thomas Coleman; executive compensation & ERISA partner Adam Kaminsky; intellectual property and technology partner Amir R. Ghavi; litigation partners Una A. Dean and Joshua D. Roth; real estate partner Cyril Touchard; tax partner Michael J. Alter; corporate special counsel Howard A. Fine; corporate associates Jennifer L. Beal, Adam B. Cohen, Dallas Cruz, Hana Nah, and Colum J. Weiden; environmental associates Samuel K. Dykstra and Mary Beth Phipps; executive compensation & ERISA associate Samantha Steinfeld Rozell; intellectual property and technology associates Daniel E. Stern and Marli Sussman; litigation associate Megan M. Howe; tax associate Ryan L. Conley; real estate associate Jing Jin; and corporate law clerks Aleksandr Galinskiy and Brian Klapow.